Content Conference Coverage Conferences EASL2017
EASL 2017: International Liver Congress Starts This Week in Amsterdam
- Details
- Category: HBV Treatment
- Created on Thursday, 13 April 2017 00:00
The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at aidsmap.com will be providing on-site coverage of meeting highlights.
EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: Approved HBV Drugs
- Created on Tuesday, 25 April 2017 00:00
People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the EASL International Liver Congress last week in Amsterdam.
EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- Details
- Category: HBV Treatment Guidelines
- Created on Tuesday, 25 April 2017 00:00
The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.
EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Created on Wednesday, 03 May 2017 00:00
A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.
EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Created on Thursday, 20 April 2017 00:00
The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.
More Articles...
- EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
- EASL 2017: WHO Releases Global Hepatitis Report
- EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
- EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
- EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
- EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- EASL 2017: Curing Hepatitis C Reduces Cardiovascular Risk
- EASL 2017: European HCV Treatment Access Survey Shows Big Variations in Eligibility
- EASL 2017: Norfloxacin Reduces Risk of Death for People with Decompensated Cirrhosis
Web Design and Development by